menu
    • menu

    Company profile for Pilatus Biosciences

    NEW Drugs in Dev: 1
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Pilatus Biosciences is at the forefront of discovering and developing first-in-class antibodies and bifunctional proteins targeting metabolic checkpoints. Their innovative approach aims to reprogram the immune microenvironment to enhance the body’s ability to combat cancer. By targeting key metabolic pathways, Pilatus seeks to develop novel therapies that can improve cancer treatment outcomes and potentially revolutionize im...
    Pilatus Biosciences is at the forefront of discovering and developing first-in-class antibodies and bifunctional proteins targeting metabolic checkpoints. Their innovative approach aims to reprogram the immune microenvironment to enhance the body’s ability to combat cancer. By targeting key metabolic pathways, Pilatus seeks to develop novel therapies that can improve cancer treatment outcomes and potentially revolutionize immuno-oncology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Pilatus BiosciencesSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Superlab Suisse Lausanne, Lab 5 Route de la Corniche 6 1066 Epalinges
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.pilatusbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pilatus Biosciences Announces First Patient Dosed In Phase 1
    Pilatus Biosciences Announces First Patient Dosed In Phase 1

    12 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260308705893/en/Pilatus-Biosciences-Announces-First-Patient-Dosed-in-Phase-1-Trial-of-First-in-Class-Metabolic-Checkpoint-Antibody-PLT012-in-Solid-Tumors

    BUSSINESSWIRE
    12 Mar 2026
    Share Share
    Pilatus Biosciences Granted FDA Fast Track For PLT012
    Pilatus Biosciences Granted FDA Fast Track For PLT012

    19 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260219271062/en/Pilatus-Biosciences-Receives-FDA-Fast-Track-Designation-for-Metabolic-Checkpoint-Inhibitor-PLT012-in-Hepatocellular-Carcinoma

    BUSINESSWIRE
    19 Feb 2026
    Share Share
    Pilatus Biosciences Clears FDA IND For PLT012, Anti-CD36 Antibody
    Pilatus Biosciences Clears FDA IND For PLT012, Anti-CD36 Antibody

    15 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251212767192/en/Pilatus-Biosciences-Announces-FDA-Clearance-of-IND-Application-for-PLT012-a-First-in-Class-Anti-CD36-Metabolic-Checkpoint-Antibody-in-Solid-Tumors

    BUSINESSWIRE
    15 Dec 2025
    Share Share
    Pilatus to Present PLT012 Tumor Immunity Data at SITC 2025
    Pilatus to Present PLT012 Tumor Immunity Data at SITC 2025

    30 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pilatus-biosciences-to-present-new-preclinical-data-highlighting-plt012s-ability-to-induce-durable-anti-tumor-immunity-through-immunometabolic-reprogramming-of-the-tumor-microenvironment-at-sitc-2025-annual-meeting-302599643.html

    PR NEWSWIRE
    30 Oct 2025
    Share Share
    Pilatus Bio Secures Global Patent For CD36-Targeted Immunotherapy
    Pilatus Bio Secures Global Patent For CD36-Targeted Immunotherapy

    14 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251014693867/en/Pilatus-Biosciences-Announces-Issuance-of-Foundational-Global-Patent-Covering-Novel-CD36-Targeted-Immunotherapy

    BUSINESSWIRE
    14 Oct 2025
    Share Share
    Pilatus, Roche to Test PLT012 in Hepatocellular Carcinoma
    Pilatus, Roche to Test PLT012 in Hepatocellular Carcinoma

    13 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250813741707/en/Pilatus-Biosciences-Announces-Clinical-Trial-Collaboration-with-Roche-to-Evaluate-PLT012-in-First-in-Human-Study-in-Hepatocellular-Carcinoma

    BUSINESSWIRE
    13 Aug 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search